Syed Wahid Husain

Address:

1436 Hallwood Rd, Catonsville, MD 21228

VIN:

2HGFA55537H709506

Make:

HONDA

Model:

CIVIC

Year:

2007

US Patent:

54240735, Jun 13, 1995

Filed:

Oct 14, 1993

Appl. No.:

8/136090

Inventors:

Aquilur Rahman - Gaithersburg MD
Rafael Rafaeloff - Tel-Aviv, IL
Syed R. Husain - Gaithersburg MD

Assignee:

Georgetown University - Washington DC

International Classification:

A61K 9127

US Classification:

424450

Abstract:

Liposomal-encapsulated taxol or an antineoplastic derivative thereof or a mixture thereof is provided which is used to effect a therapeutically enhanced method of treating cancer, and which may be used advantageously in combination with hyperthermia. The liposomes confer enhanced stability and solubility to taxol or derivatives thereof.

US Patent:

56480903, Jul 15, 1997

Filed:

May 26, 1995

Appl. No.:

8/451258

Inventors:

Aquilur Rahman - Gaithersburg MD
Rafael Rafaeloff - Tel-Aviv, IL
Syed Rafat Husain - Gaithersburg MD

Assignee:

Georgetown University - Washington DC

International Classification:

A61K 9127

US Classification:

424450

Abstract:

Liposomal-encapsulated taxol or an antineoplastic derivative thereof or a mixture thereof is provided which is used to effect a therapeutically enhanced method of treating cancer, and which may be used advantageously in combination with hyperthermia. The liposomes confer enhanced stability and solubility to taxol or derivatives thereof.

US Patent:

20200282020, Sep 10, 2020

Filed:

Sep 7, 2018

Appl. No.:

16/645431

Inventors:

- Silver Spring MD, US
Kathryn C. Zoon - Kensington MD, US
Syed R. Husain - Gaithersburg MD, US
Daniel S. Green - Silver Spring MD, US

Assignee:

The United States of America, as represented by the Secretary, Department of Health and Human Servic - Silver Spring MD

International Classification:

A61K 38/21
C07K 16/28
A61K 35/15
A61P 35/00
A61K 38/17

Abstract:

Methods and compositions are disclosed for treating a subject with a cancer. The compositions can include a chimeric molecule comprising an agent that specifically binds the interleukin 4 receptor (IL-4R) and a toxic moiety, an interferon alpha (IFNα), and an interferon gamma (IFNγ). In some non-liming embodiments, the compositions can also include monocytes. The methods disclosed herein include administering a therapeutically effective amount of the compositions taught herein to a subject with cancer, thereby treating the cancer in the subject, wherein cells in the cancer express IL-4R. In some non-liming embodiments, the methods can also include administering monocytes.